Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
HUMAN dipeptidyl peptidase 4 (DPP-4) |
Target Info
|
Inhibitor |
[3], [4] |
| References |
Top |
| REF 1 |
FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
|
| REF 2 |
ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
|
| REF 3 |
DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
|
| REF 4 |
Effects of Dipeptidyl Peptidase 4 Inhibition on Inflammation in Atherosclerosis: A 18 F-fluorodeoxyglucose Study of a Mouse Model of Atherosclerosis and Type 2 DiabetesAtherosclerosis. 2020 Apr 10. pii: S0021-9150(20)30194-5.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
